Key points are not available for this paper at this time.
Previous cross-sectional studies have identified wide practice pattern variations in the use of peripheral vascular interventions (PVIs) for the treatment of claudication. However, there are limited data on longitudinal practice patterns. We aimed to describe the temporal trends and charges associated with PVI use for claudication over the past 12 years in the United States.
This study in the Journal of the American Heart Association found that GLP-1 receptor agonists were associated with a lower risk of major adverse cardiovascular events in adults with obesity and autoimmune disease. This adds to the growing body of evidence for the cardiovascular benefits of GLP-1 RAs in specific high-risk populations.
Dun et al. (Wed,) studied this question.